Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

D. Russell-Jones; A. Vaag; O. Schmitz; B. K. Sethi; N. Lalic; S. Antic; M. Zdravkovic; G. M. Ravn; R. Simó; on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group

首页> 外文期刊>Diabetologia >Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

【24h】

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

机译：利拉鲁肽vs甘精胰岛素和安慰剂联合二甲双胍和磺脲类药物治疗2型糖尿病（LEAD-5 met + SU）：一项随机对照试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Aims/hypothesis The aim of the study was to compare the efficacy and safety of liraglutide in type 2 diabetes mellitus vs placebo and insulin glargine (A21Gly,B31Arg,B32Arg human insulin), all in combination with metformin and glimepiride.

机译：目的/假设该研究的目的是比较利拉鲁肽在2型糖尿病患者与安慰剂和甘精胰岛素（A21Gly，B31Arg，B32Arg人胰岛素）以及二甲双胍和格列美脲的组合中的疗效和安全性。

著录项

来源
《Diabetologia》 |2009年第10期|p.2046-2055|共10页
作者
D. Russell-Jones; A. Vaag; O. Schmitz; B. K. Sethi; N. Lalic; S. Antic; M. Zdravkovic; G. M. Ravn; R. Simó; on behalf of the Liraglutide Effect and Action in Diabetes 5 (LEAD-5) met+SU Study Group;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类
关键词
DPP; 4; Exenatide; Incretin; Insulin glargine; LEAD; 5;

机译：DPP;4;艾塞那肽;肠激肽;甘精胰岛素;铅;5;

相似文献

外文文献
中文文献
专利

1. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial [J] . D. Russell-Jones, A. Vaag, O. Schmitz, Diabetologia: clinical and experimental diabetes and metabolism . 2009,第10期

机译：利拉鲁肽vs甘精胰岛素和安慰剂联合二甲双胍和磺脲类药物治疗2型糖尿病（LEAD-5 met + SU）：一项随机对照试验
2. Combination therapy with insulin glargine plus metformin but not insulin glargine plus sulfonylurea provides similar glycemic control to triple oral combination therapy in patients with type 2 diabetes uncontrolled with dual oral agent therapy [J] . Journal of diabetes and its complications . 2015,第8期

机译：在未接受双重口服药物治疗的2型糖尿病患者中，甘精胰岛素加二甲双胍联合治疗但甘精胰岛素加磺酰脲未对三联口服联合治疗提供相似的血糖控制
3. Metformin versus placebo in combination with insulin analogues in patients with type 2 diabetes mellitus—the randomised, blinded Copenhagen Insulin and Metformin Therapy (CIMT) trial [J] . Allan Vaag, Bendix Carstensen, Bianca Hemmingsen, BMJ Open . 2016,第2期

机译：二甲双胍与安慰剂联合胰岛素类似物治疗2型糖尿病患者的随机，盲法哥本哈根胰岛素和二甲双胍治疗（CIMT）试验
4. Switching to insulin glargine 300 U/mL from other basal insulin analogues provides less 24-hour glucose variability in hospitalized patients with type 1 diabetes [C] . V.V. Klimontov, E.A. Koroleva, O.N. Fazullina International Multiconference Bioinformatics of Genome Regulation and StructureSystems Biology . 2018

机译：从其他基础胰岛素类似物转换为甘精胰岛素300 U / mL可使住院的1型糖尿病患者的24小时葡萄糖变异性降低
5. A randomized placebo-controlled trial of pioglitazone to improve metabolic control in adolescents with type 1 diabetes mellitus. [D] . Zdravkovic, Vera. 2005

机译：吡格列酮对改善1型糖尿病青少年的代谢控制的随机安慰剂对照试验。
6. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial [O] . D. Russell-Jones, A. Vaag, O. Schmitz, -1

机译：利拉鲁肽vs甘精胰岛素和安慰剂联合二甲双胍和磺脲类药物治疗2型糖尿病（LEAD-5 met + SU）：一项随机对照试验
7. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial [O] . D. Russell-Jones, null null, A. Vaag, 2009

机译：利拉鲁肽vs甘精胰岛素和安慰剂联合二甲双胍和磺脲类药物治疗2型糖尿病（LEAD-5 met + SU）：一项随机对照试验

Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial

摘要

著录项

相似文献

相关主题

期刊订阅